703 related articles for article (PubMed ID: 24775724)
1. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
4. Current role of immunotherapy for the treatment of prostate cancer.
Porfyris O; Kalomoiris P
J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
[TBL] [Abstract][Full Text] [Related]
5. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
[TBL] [Abstract][Full Text] [Related]
7. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
Reimers MA; Slane KE; Pachynski RK
Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
Handy CE; Antonarakis ES
Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
[TBL] [Abstract][Full Text] [Related]
10. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
Dreicer R
Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
13. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
14. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
15. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
16. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
17. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
[TBL] [Abstract][Full Text] [Related]
18. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
19. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
Peppercorn J; Armstrong A; Zaas DW; George D
Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
Gulley JL; Madan RA; Heery CR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]